期刊文献+

盐酸二甲双胍缓释片释放度及体内体外相关性研究 被引量:5

Study on Correlation Between in Vitro Release and in Vivo Absorption of Metformin Hydrochloride Sustained-Release Tablets
原文传递
导出
摘要 目的测定受试制剂盐酸二甲双胍缓释片的体外释放度,并进行体内体外相关性研究。方法采用转篮法测定释放度,紫外分光光度法测定含量,测定波长233 nm,计算受试制剂与原研产品释放曲线的相似因子f2,进行释放度的比较;单剂量口服受试制剂后测定血药浓度,将体外释放度数据与用Wagner-Nelson方法计算的药物体内吸收百分数进行线性回归后,进行体内体外相关性研究。结果受试制剂与原研产品体外释药曲线相似,受试制剂的体内体外相关性良好。结论受试制剂体外释放度合格,与原研产品有相似的体外释放特性,且可以通过体外释放曲线预测体内情况。 OBJECTIVE To study the correlation between the in vitro release and in vivo absorption of mefformin hydrochloride sustained-release tablets. METHODS The rotatory-basket method was used to determine the release rate, and UV spectrophotometer at 233 nm was used to assay the concentration. Similarity factor was calculated to compare the release rates of the test product and the original product. A single dose of metformin hydrochloride sustained-release tablets was given to 20 healthy volunteers, and the met- formin hydroch]oride concentrations in plasma at different time were determined. RESULTS The test product and the original product showed similar in vitro release characteristics, and the test product demonstrated good in vitro-in vivo correlation. CONCLUSION The in vitro release characteristic of the test product is qualified, and similar to that of the original product. The in vitro release curve of the test product can be used to evaluate its in vivo absorption.
作者 杨婧 齐宪荣
出处 《中国药学杂志》 CAS CSCD 北大核心 2011年第22期1727-1730,共4页 Chinese Pharmaceutical Journal
关键词 盐酸二甲双胍 缓释片 释放度 体内体外相关性 metformin hydrochloride sustained-release tablets in-vitro release in vitro-in vivo correlation
  • 相关文献

参考文献4

二级参考文献17

  • 1张霖泽,王兰勤.口服控释制剂的质量评价[J].中国药学杂志,1995,30(6):366-371. 被引量:34
  • 2国家食品药品监督管理局.化学药物口服缓释制剂药学研究技术指导原则[S].2007.
  • 3国家食品药品监督管理局.《口服缓控释制剂药学研究技术指导原则》[S].2007.9.
  • 4USP30-NF25. General charpters: < 1088 > in vitro and in vivo evaluation of dosage forms [ S ]. 2007.
  • 5FDA. Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations[ EB/OL]. ( 1997 - 09 ). http://www, fda. gov/cder/guid- ance/1306fnl, pdf.
  • 6FDA. Guidance for industry: scale up and post approval changes modified release (SUPAC-MR) [ EB/OL]. ( 1997 - 10). http :// www. fda. gov/cder/guidance/1214fnt, pdf.
  • 7Fujioka K, Brazg RL, Raz Z, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XP ) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo controlled study. Diabetes Obes Metab, 2005,7:28-39.
  • 8Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab, 2003, 29:79-81.
  • 9Sratton IM,Adler AI, Neff HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes(UKPDS) : prospective observational study. BMJ, 2000, 321:405-412.
  • 10Blonde L, Dailey GE, Jabbour SA, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin, 2004,20:565-572.

共引文献32

同被引文献47

引证文献5

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部